Health & Life Co., Ltd. (1781) AI Stock Analysis

Health & Life Co., Ltd.

(TPEx:1781)

Select Model

Rating:38Underperform

Price Target:TWD 8.00▼(-6.98% Downside)

Action:initiatedcoverage

Date:11/10/26

Primarily driven by weak financial performance with revenue collapse and net losses; unattractive valuation due to negative P/E and bearish technicals with price below moving averages.

Positive Factors

Manageable LeverageModerate leverage gives Health & Life a stronger financial base than an overextended balance sheet would provide. Substantial equity relative to assets may preserve borrowing capacity and strategic flexibility, helping the company withstand operating weakness while it works to restore profitability.

Negative Factors

Revenue ContractionRevenue contraction weakens the foundation for operating leverage and makes it harder to absorb fixed costs across the business. Unless the decline reverses, lower scale can limit investment capacity, reduce the opportunity to rebuild margins, and prolong the company’s current earnings pressure.

Health & Life Co., Ltd. (1781) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 407.71M
Dividend Yield: ―
Average Volume (3M): 44.63K
Price to Earnings (P/E): -8.0
Beta (1Y): 0.43
Revenue Growth: -12.12%
EPS Growth: -17.29%
Country: TW
Employees: 120
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Health & Life Co., Ltd. Business Overview & Revenue Model

Company Description

Health & Life Co., Ltd. is a global provider of medical devices. Established in 1996 and headquartered in New Taipei City, Taiwan, the company specializes in developing and distributing solutions for critical health sectors, including cardiovascular...

Health & Life Co., Ltd. Financial Statement Overview

Summary

Weak performance with sharp revenue drop to 398M from 706M, net loss of 62M, negative margins and free cash flow, despite moderate leverage.

Income Statement

22Negative

Balance Sheet

47Neutral

Cash Flow

29Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	400.09M	398.05M	706.39M	601.17M	797.54M	811.88M
Gross Profit	52.62M	70.12M	147.74M	93.11M	97.72M	45.76M
EBITDA	-31.11M	-46.70M	55.63M	-7.84M	11.85M	-63.05M
Net Income	-50.67M	-61.67M	24.24M	-33.23M	-17.55M	-62.34M
Balance Sheet
Total Assets	655.77M	723.13M	817.26M	710.79M	799.76M	776.39M
Cash, Cash Equivalents and Short-Term Investments	222.42M	247.94M	277.35M	151.05M	156.98M	200.32M
Total Debt	198.03M	196.97M	214.14M	113.60M	189.45M	134.81M
Total Liabilities	352.54M	402.56M	424.21M	375.42M	427.18M	398.22M
Stockholders Equity	303.23M	320.57M	393.05M	335.37M	372.58M	378.18M
Cash Flow
Free Cash Flow	-25.33M	-5.01M	30.14M	76.82M	-93.02M	-145.04M
Operating Cash Flow	-16.54M	3.18M	33.35M	84.91M	-80.69M	-131.15M
Investing Cash Flow	41.19M	41.96M	-89.81M	-8.78M	-10.32M	-16.02M
Financing Cash Flow	-15.78M	-21.91M	128.68M	-74.67M	25.91M	-91.10M

Health & Life Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1781 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1781	38Underperform	TWD 407.71M	-8.04	―	―	-12.12%	-17.29%

* General Sector Average

Performance Comparison

TW:1781 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1781	Health & Life Co., Ltd.	8.60	-3.40	-28.33%
TW:4115	Sunder Biomedical Tech. Co., Ltd.	6.97	-1.23	-15.00%
TW:4117	General Biologicals Corp.	7.41	-4.79	-39.26%
TW:4186	Taiwan Advance Bio-Pharmaceutical, Inc.	7.00	-5.95	-45.95%
TW:6549	TaiwanJ Pharmaceuticals Co., Ltd.	6.25	-1.61	-20.48%
TW:6621	Unipharma Co., Ltd.	12.00	-0.20	-1.64%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Health & Life Co., Ltd. AI Stock Analysis